AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2015
Mar 24, 2015
31523_dirs_2015-03-24_96f622b8-0d71-46d0-be6e-6df7794cf3fb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2015-03-20
Reporting Person: Kirk John (VP, Regulatory Affairs)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-03-20 | Common stock | M | 10110 | $11.5093 | Acquired | 60110 | Direct |
| 2015-03-20 | Common stock | S | 10110 | $11.5093 | Disposed | 50000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-03-20 | Stock options (right to buy) | $6.06 | M | 10110 | Disposed | 2021-06-16 | Common stock (10110) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.98. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.98. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.